CMPRHIGH SIGNALFINANCIAL10-K

Net income declined substantially while capital expenditure increased meaningfully, indicating a challenging operational year with continued investment spending.

The dramatic reduction in profitability alongside increased capital spending suggests either significant one-time charges, operational headwinds, or major investments that have not yet generated returns. The combination of reduced share buybacks and increased debt indicates management is conserving cash while maintaining investment priorities, which could signal either financial prudence or emerging capital constraints.

Comparing 2025-08-08 vs 2024-08-09View on EDGAR →
FINANCIAL ANALYSIS

The company experienced a substantial decline in net income while simultaneously increasing capital expenditures by 62.1% and reducing share buybacks by roughly half. Despite the profitability challenges, the balance sheet shows modest strengthening with cash increasing 14.8% and total debt rising 23.4%. Operating cash flow declined 15%, but the company maintained its investment posture, suggesting management believes current spending will generate future returns despite near-term profitability pressures.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-91.4%
$173.7M$15.0M

Net income declined 91.4% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
+62.1%
$54.9M$89.0M

Capital expenditure jumped 62.1% — major investment cycle underway; assess returns on deployment.

Share Buybacks
Cash Flow
-50.5%
$157.0M$77.8M

Buyback activity reduced 50.5% — capital being redeployed elsewhere or cash conservation underway.

Total Debt
Balance Sheet
+23.4%
$839.4M$1.0B

Debt rose 23.4% — additional borrowing for investment or operations; monitor coverage ratios.

Inventory
Balance Sheet
+16.3%
$97.0M$112.9M

Inventory built 16.3% — monitor whether demand supports this build or if write-downs may follow.

Operating Cash Flow
Cash Flow
-15%
$350.7M$298.1M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Cash & Equivalents
Balance Sheet
+14.8%
$203.8M$234.0M

Cash grew 14.8% — improving liquidity position supports investment and shareholder returns.

Current Liabilities
Balance Sheet
+14.3%
$664.0M$758.7M

Current liabilities rose 14.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2025-08-08
PRIOR — 2024-08-09
ADDED
As of August 4, 2025, there were 24,481,085 Cimpress plc ordinary shares outstanding.
Changes in and Disagreements with Accountants and Financial Disclosure 95 Item 9A.
This optionality creates healthy pressure on the central teams who provide such services to deliver compelling value to our businesses.
The combination of decentralization for most aspects of how we run Cimpress with a select few shared strategic capabilities in which we invest centrally is intended to engender customer-centric, entrepreneurial and owner mindsets across a wide set of geographies, products and customer types while also enabling significant synergies and knowledge-sharing across Cimpress.
Our Uppermost Financial Objective Our uppermost financial objective is to maximize our intrinsic value per share ( IVPS ).
+7 more — sign up free →
REMOVED
As of August 5, 2024, there were 25,066,128 Cimpress plc ordinary shares outstanding.
Changes in and Disagreements with Accountants and Financial Disclosure 97 Item 9A.
This optionality, we believe, creates healthy pressure on the central teams who provide such services to deliver compelling value to our businesses.
Our Uppermost Financial Objective Our uppermost financial objective is to maximize our intrinsic value per share.
We define unlevered free cash flow as adjusted free cash flow plus cash interest payments, partially offset by cash interest received on our cash and marketable securities.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →